REGENXBIO Inc. Stock price

Equities

RGNX

US75901B1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
21.07 USD -5.00% Intraday chart for REGENXBIO Inc. -6.36% +17.38%
Sales 2024 * 134M Sales 2025 * 218M Capitalization 1.03B
Net income 2024 * -211M Net income 2025 * -134M EV / Sales 2024 * 6.56 x
Net cash position 2024 * 151M Net cash position 2025 * 175M EV / Sales 2025 * 3.93 x
P/E ratio 2024 *
-5.11 x
P/E ratio 2025 *
-8.87 x
Employees 344
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.00%
1 week-6.36%
Current month+20.81%
1 month+5.88%
3 months+13.65%
6 months+19.17%
Current year+17.38%
More quotes
1 week
20.94
Extreme 20.94
22.42
1 month
17.86
Extreme 17.86
28.80
Current year
11.83
Extreme 11.83
28.80
1 year
11.83
Extreme 11.83
28.80
3 years
11.83
Extreme 11.83
46.46
5 years
11.83
Extreme 11.83
59.98
10 years
7.07
Extreme 7.0701
85.10
More quotes
Managers TitleAgeSince
Founder 49 08-07-15
Director of Finance/CFO 56 09-07-31
Chief Tech/Sci/R&D Officer - 15-10-31
Members of the board TitleAgeSince
Director/Board Member 69 21-09-02
Director/Board Member 74 15-10-14
Director/Board Member 71 15-04-30
More insiders
Date Price Change Volume
24-03-28 21.07 -5.00% 487,057
24-03-27 22.18 +2.35% 561,385
24-03-26 21.67 +0.37% 345,696
24-03-25 21.59 -0.87% 302,600
24-03-22 21.78 -3.20% 279,146

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
21.07 USD
Average target price
39.83 USD
Spread / Average Target
+89.05%
Consensus
  1. Stock
  2. Equities
  3. Stock REGENXBIO Inc. - Nasdaq